论文部分内容阅读
目的:探究纳洛酮在慢阻肺合并心衰患者中的应用效果。方法:选取本院在2016年1月至2017年1月期间收治的60例慢阻肺合并心衰患者参与研究,将60例患者按照不同的治疗方式分成对照组和观察组,每组各30例。对照组患者采取常规治疗,观察组则在对照组的基础上给予纳洛酮进行治疗,比较两组患者治疗前后的肺功能指标以及临床疗效。结果:两组患者经过治疗后,肺功能指标均得到明显改善,观察组患者的肺功能改善情况较对照组更佳;观察组患者的临床疗效为96.67%,远高于对照组的临床疗效76.76%,且差异具有统计学意义(P<0.05)。结论:纳洛酮用于治疗慢阻肺合并心衰患者中,临床疗效显著,可以明显提高患者肺功能,有效改善患者的心率,值得广泛推荐。
Objective: To investigate the application of naloxone in COPD patients with heart failure. Methods: Sixty patients with chronic obstructive pulmonary disease who were admitted to our hospital from January 2016 to January 2017 were enrolled in this study. Sixty patients were divided into control group and observation group according to different treatment methods example. Patients in the control group were treated routinely, while those in the observation group were treated with naloxone on the basis of the control group. The pulmonary function indexes and clinical efficacy of the two groups before and after treatment were compared. Results: The lung function indexes of both groups were significantly improved after treatment. The improvement of pulmonary function in observation group was better than that in control group. The clinical effect in observation group was 96.67%, much higher than that in control group (76.76%) %, And the difference was statistically significant (P <0.05). Conclusion: Naloxone is effective in treating patients with chronic obstructive pulmonary disease and heart failure, and has significant clinical effect. It can significantly improve pulmonary function and improve heart rate of patients. It is widely recommended.